The Role of Topical Immune Response Modifiers in Skin Cancer
Authors:
- Robert B SkinnerRSRobert B Skinner
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (13) , 1657-1664
Abstract
Topical immune response modifiers include imiquimod and resiquimod. The mechanism of action of immune response modifiers is complex and not completely understood. It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines. Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget’s disease.Keywords
This publication has 33 references indexed in Scilit:
- Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% CreamDermatologic Surgery, 2006
- Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor AgonistsDermatologic Surgery, 2004
- Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier ImiquimodJournal of Investigative Dermatology, 2004
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJournal of the American Academy of Dermatology, 2004
- Randomized, Single-Blind, Placebo-Controlled Studyof Topical Application of the Immune Response ModulatorResiquimod in HealthyAdultsAntimicrobial Agents and Chemotherapy, 2003
- Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier ImiquimodJNCI: Journal of the National Cancer Institute, 2003
- Successful topical immunotherapy of bowenoid papulosis with imiquimod.British Journal of Dermatology, 2001
- Imiquimod 5% cream in the treatment of Bowen's diseaseJournal of the American Academy of Dermatology, 2001
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Nonmelanoma Cancers of the SkinNew England Journal of Medicine, 1992